Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Tong Ren Tang Technologies Co. Ltd.

北京同仁堂科技發展股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1666)

VOLUNTARY ANNOUNCEMENT
RECEIVING THE CERTIFICATE OF REGISTRATION OF PROPRIETARY CHINESE MEDICINE

This announcement is made by the board of directors (the "**Board**") of Tong Ren Tang Technologies Co. Ltd. (the "**Company**", and together with its subsidiaries, the "**Group**") on a voluntary basis for the purpose of keeping shareholders and potential investors of the Company informed of the latest business development of the Group.

The Board is pleased to announce that the Company's subsidiary, Beijing Tong Ren Tang (Macau) Company Limited ("**TRT Macau**") received the Certificate of Registration of Proprietary Chinese Medicine (《中成藥註冊證明書》) issued by the Pharmaceutical Administration Bureau of Macao Special Administrative Region Government, allowing "Jin Chai Shi Hu San【Tong Ren Tang】" (金釵石斛散【同仁堂】) to be sold in the Macao Special Administrative Region of the People's Republic of China ("**Macao**"). The relevant details are as follows:

I. Basic Information of the Medicine

Name of the medicine: Jin Chai Shi Hu San【Tong Ren Tang】(金釵石斛散【同仁堂】)

Registrant and address: BEIJING TONG REN TANG (MACAU) COMPANY LIMITED at Unit B, 8th Floor, Taiping Industrial Building (Phase 1), No. 101-105-A, Rua do Campo, Macao

Registration number: MAC-C00315

II. Other Related Information of the Medicine

The function and main indications of the "Jin Chai Shi Hu San【Tong Ren Tang】" are to treat conditions such as heat disease consuming fluid, dry mouth, vexation and thirst, stomach yin deficiency, reduced food intake, retching, deficiency heat after recovering from an illness, yin deficiency with effulgent fire, steaming bone and consumptive fever, dim and blurred vision, limp witting sinew and bone. As of the date of this announcement, the Group has cumulatively invested approximately HK$2 million (unaudited) in the research and development of "Jin Chai Shi Hu San【Tong Ren Tang】".

III. Impact on the Company and Risk Warning

Upon obtaining the Certificate of Registration of Proprietary Chinese Medicine issued by the Pharmaceutical Administration Bureau of Macao Special Administrative Region Government, "Jin Chai Shi Hu San【Tong Ren Tang】" produced by the TRT Macau can be sold in Macao, which is beneficial to the Group's market expansion. The obtaining of the aforementioned certificate of registration will not have any material impact on the production, operation and performance of the Company for the time being. The sales of pharmaceutical products can be influenced by factors such as change in the policy environment, exchange rate fluctuations and market competition in the Macao region.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Tong Ren Tang Technologies Co. Ltd.
Zhang Yi
Chairman of the Board

Beijing, the PRC
20 April 2026

As at the date of this announcement, the Board comprises Mr. Zhang Yi, Mr. Zhang Chun You, and Ms. Wen Kai Ting as executive Directors, Ms. Du Xin and Ms. Feng Li as non-executive Directors, Ms. Chan Ching Har, Eliza and Mr. Zhan Yuan Jing and Mr. Siu, Paul Yu Hey as independent non-executive Directors, Mr. Zhu Dong Sheng as employee Director.